{"id":"cggv:2305ec95-325d-4ebe-9401-121705e49660v1.1","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:2305ec95-325d-4ebe-9401-121705e49660_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10020","date":"2022-03-22T16:00:00.000Z","role":"Approver"},{"id":"cggv:2305ec95-325d-4ebe-9401-121705e49660_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10020","date":"2022-06-02T14:17:57.240Z","role":"Publisher"}],"earliestArticle":{"id":"https://pubmed.ncbi.nlm.nih.gov/17054399","type":"dc:BibliographicResource","dc:abstract":"Kallmann syndrome combines anosmia, related to defective olfactory bulb morphogenesis, and hypogonadism due to gonadotropin-releasing hormone deficiency. Loss-of-function mutations in KAL1 and FGFR1 underlie the X chromosome-linked form and an autosomal dominant form of the disease, respectively. Mutations in these genes, however, only account for approximately 20% of all Kallmann syndrome cases. In a cohort of 192 patients we took a candidate gene strategy and identified ten and four different point mutations in the genes encoding the G protein-coupled prokineticin receptor-2 (PROKR2) and one of its ligands, prokineticin-2 (PROK2), respectively. The mutations in PROK2 were detected in the heterozygous state, whereas PROKR2 mutations were found in the heterozygous, homozygous, or compound heterozygous state. In addition, one of the patients heterozygous for a PROKR2 mutation was also carrying a missense mutation in KAL1, thus indicating a possible digenic inheritance of the disease in this individual. These findings reveal that insufficient prokineticin-signaling through PROKR2 leads to abnormal development of the olfactory system and reproductive axis in man. They also shed new light on the complex genetic transmission of Kallmann syndrome.","dc:creator":"Dodé C","dc:date":"2006","dc:title":"Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2."},"evidence":[{"id":"cggv:2305ec95-325d-4ebe-9401-121705e49660_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:60a04de2-3d9b-4c5b-bbd6-f6750c8a7c85_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:60a04de2-3d9b-4c5b-bbd6-f6750c8a7c85","type":"Proband","allele":{"id":"cggv:a7932dcf-e5ce-433a-94ea-3106ddf95403","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.364C>T (p.Arg122Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2491951"}},"firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"cggv:6c808035-c6b5-4711-80b8-1dc6bb16cbdc_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a7932dcf-e5ce-433a-94ea-3106ddf95403"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24031091","type":"dc:BibliographicResource","dc:abstract":"Kallmann syndrome (KS) is a genetically heterogeneous developmental disorder that associates hypogonadotropic hypogonadism and anosmia. Various causative genes have been identified, but their respective involvement in different world regions is poorly documented.","dc:creator":"Sarfati J","dc:date":"2013","dc:title":"Greater prevalence of PROKR2 mutations in Kallmann syndrome patients from the Maghreb than in European patients."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Patient with KS (nonsense variant)"},{"id":"cggv:6c808035-c6b5-4711-80b8-1dc6bb16cbdc","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:6c808035-c6b5-4711-80b8-1dc6bb16cbdc_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:cb951a58-4799-4905-a24d-475e070e5cc6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:cb951a58-4799-4905-a24d-475e070e5cc6","type":"Proband","allele":{"id":"cggv:69821c07-95e5-46c5-ac4e-b54fbcb40284","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.181A>G (p.Met61Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353501034"}},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Hypothalamic amenorrhoea","sex":"Female","variant":{"id":"cggv:8458ee09-2690-42de-b578-ac079d9b7132_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:69821c07-95e5-46c5-ac4e-b54fbcb40284"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/32870266","type":"dc:BibliographicResource","dc:abstract":"Functional hypothalamic amenorrhea (HA) is a common, acquired form of hypogonadotropic hypogonadism that occurs in the setting of energy deficits and/or stress. Variability in individual susceptibility to these stressors, HA heritability, and previous identification of several rare sequence variants (RSVs) in genes associated with the rare disorder, isolated hypogonadotropic hypogonadism (IHH), in individuals with HA suggest a possible genetic contribution to HA susceptibility.","dc:creator":"Delaney A","dc:date":"2021","dc:title":"Increased Burden of Rare Sequence Variants in GnRH-Associated Genes in Women With Hypothalamic Amenorrhea."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Individual with variant in PROK2"},{"id":"cggv:8458ee09-2690-42de-b578-ac079d9b7132","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:8458ee09-2690-42de-b578-ac079d9b7132_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:aa0e7b9b-f16b-4568-a444-e2b3fb49e748_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:aa0e7b9b-f16b-4568-a444-e2b3fb49e748","type":"Proband","allele":{"id":"cggv:b7f16996-eabe-4a98-a1e8-e39a31e9f10a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.101G>A (p.Cys34Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA270915"}},"firstTestingMethod":"PCR","phenotypeFreeText":"Sense of smell <5th %ile","phenotypes":"obo:HP_0008187","sex":"Male","variant":{"id":"cggv:adda5b9d-a7bf-4ffb-8a82-c473ab3d7f5f_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b7f16996-eabe-4a98-a1e8-e39a31e9f10a"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/18559922","type":"dc:BibliographicResource","dc:abstract":"Mice deficient in prokineticin 2(PROK2) and prokineticin receptor2 (PROKR2) exhibit variable olfactory bulb dysgenesis and GnRH neuronal migration defects reminiscent of human GnRH deficiency.","dc:creator":"Cole LW","dc:date":"2008","dc:title":"Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Subject no. 3"},{"id":"cggv:adda5b9d-a7bf-4ffb-8a82-c473ab3d7f5f","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:adda5b9d-a7bf-4ffb-8a82-c473ab3d7f5f_variant_evidence_item"},{"id":"cggv:adda5b9d-a7bf-4ffb-8a82-c473ab3d7f5f_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"An aequorin-based luminescence assay was used to evaluate intracellular calcium mobilization. This variant completely eliminated the calcium mobilizing activity of PROK2 with a >1000-fold reduction at the Ec50 of the wild type."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:9ed20478-21ad-40d0-864f-36d295b9d4cd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:9ed20478-21ad-40d0-864f-36d295b9d4cd","type":"Proband","allele":{"id":"cggv:efc85928-1ae2-4a44-8c8d-5e9b8405db86","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.137G>A (p.Cys46Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353501131"}},"firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"cggv:e14a3ec6-04f1-47a5-aa64-b0bce89f8656_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:efc85928-1ae2-4a44-8c8d-5e9b8405db86"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/25077900","type":"dc:BibliographicResource","dc:abstract":"Mutations in CHD7, a gene previously implicated in CHARGE (coloboma, heart defect, choanal atresia, retardation of growth and/or development, genital hypoplasia, ear anomalies) syndrome, have been reported in patients presenting with Kallmann syndrome (KS) or congenital hypogonadotropic hypogonadism (CHH). Most mutations causing CHARGE syndrome result in premature stop codons and occur de novo, but the proportion of truncating vs nontruncating mutations in KS and CHH patients is still unknown.","dc:creator":"Marcos S","dc:date":"2014","dc:title":"The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical CHARGE patients."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Individual with variant in PROK2"},{"id":"cggv:e14a3ec6-04f1-47a5-aa64-b0bce89f8656","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:e14a3ec6-04f1-47a5-aa64-b0bce89f8656_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:2305ec95-325d-4ebe-9401-121705e49660_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":5.2},{"id":"cggv:5c3257a3-e03f-4e3e-aa4e-e43322fb0120_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:5c3257a3-e03f-4e3e-aa4e-e43322fb0120","type":"Proband","allele":{"id":"cggv:16432767-0b83-49c6-9949-8973f471e3b8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.-4C>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/801987"}},"firstTestingMethod":"PCR","sex":"UnknownEthnicity","variant":{"id":"cggv:dd8fca3e-310e-4927-9094-38256dcae716_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:16432767-0b83-49c6-9949-8973f471e3b8"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17054399"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Sporadic Case 1"},{"id":"cggv:dd8fca3e-310e-4927-9094-38256dcae716","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:dd8fca3e-310e-4927-9094-38256dcae716_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:e9c78940-8820-4443-bb16-7f0a61385322_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e9c78940-8820-4443-bb16-7f0a61385322","type":"Proband","allele":{"id":"cggv:0861077d-4cb0-4225-b766-547a0a51d42b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.234_235insT (p.Asn79Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2499214027"}},"firstTestingMethod":"PCR","sex":"Female","variant":{"id":"cggv:91d3fa35-7c8a-4aa2-a6c4-acb313d33595_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:0861077d-4cb0-4225-b766-547a0a51d42b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17054399"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"II-4"},{"id":"cggv:91d3fa35-7c8a-4aa2-a6c4-acb313d33595","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:91d3fa35-7c8a-4aa2-a6c4-acb313d33595_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:af7f693c-e15b-4129-b40b-d031cf21c00c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:af7f693c-e15b-4129-b40b-d031cf21c00c","type":"Proband","allele":{"id":"cggv:efc85928-1ae2-4a44-8c8d-5e9b8405db86"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"cggv:a6e01d24-1378-48e5-bbbf-b49ade61dc06_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:efc85928-1ae2-4a44-8c8d-5e9b8405db86"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24031091"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Patient with KS (1st missense variant)"},{"id":"cggv:a6e01d24-1378-48e5-bbbf-b49ade61dc06","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:a6e01d24-1378-48e5-bbbf-b49ade61dc06_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:97d69f9e-2949-4408-9a0b-c9a9ccab8081_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:97d69f9e-2949-4408-9a0b-c9a9ccab8081","type":"Proband","allele":{"id":"cggv:052b116d-22e3-4199-9b7f-e52a37ebbd25","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.217C>T (p.Arg73Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252842"}},"firstTestingMethod":"PCR","phenotypeFreeText":"Basal LH: 0.1 IU/L, Basal FSH: 0.5 IU/L, Basal TT: 26 ng/dl, Basal mean testical size: 1 ml, Final mean testicular volume: 8 ml, Maximum sperm count: 8 million/ml","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"cggv:0bc82c72-d888-4c96-ac7e-dc41bf468058_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:052b116d-22e3-4199-9b7f-e52a37ebbd25"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:BiallelicHomozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26141714","type":"dc:BibliographicResource","dc:abstract":"Do patients with congenital combined pituitary hormone deficiency (CCPHD) have different responses to gonadotrophin-induced spermatogenesis compared with those with idiopathic hypogonadotropic hypogonadism (IHH)?","dc:creator":"Mao J","dc:date":"2015","dc:title":"Congenital combined pituitary hormone deficiency patients have better responses to gonadotrophin-induced spermatogenesis than idiopathic hypogonadotropic hypogonadism patients."}},"zygosity":{"id":"cg:BiallelicHomozygous"},"rdfs:label":"Reference number 6"},{"id":"cggv:0bc82c72-d888-4c96-ac7e-dc41bf468058","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:0bc82c72-d888-4c96-ac7e-dc41bf468058_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:2ee74a66-60de-4fec-9552-9f6ceac8e338_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:2ee74a66-60de-4fec-9552-9f6ceac8e338","type":"Proband","allele":{"id":"cggv:052b116d-22e3-4199-9b7f-e52a37ebbd25"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0008187","obo:HP_0000819","obo:HP_0000939"],"sex":"Female","variant":{"id":"cggv:082af6bd-1b3b-4767-90e8-0275553903bb_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:052b116d-22e3-4199-9b7f-e52a37ebbd25"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/18559922"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Subject no. 4"},{"id":"cggv:082af6bd-1b3b-4767-90e8-0275553903bb","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:082af6bd-1b3b-4767-90e8-0275553903bb_variant_evidence_item"},{"id":"cggv:082af6bd-1b3b-4767-90e8-0275553903bb_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Functional analysis in CHO cells demonstrated a 7-fold decrease in calcium-mobilizing activity with the R73C mutant at the EC50 of wild type."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:0cdd0512-bced-4941-8e9f-2c3a56878564_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:0cdd0512-bced-4941-8e9f-2c3a56878564","type":"Proband","allele":{"id":"cggv:4a6aea08-07f0-4a89-a900-8c287e86355c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.163del (p.Ser54_Ile55insTer)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252841"}},"firstTestingMethod":"PCR","phenotypeFreeText":"cerebrovascular event (age 62) convulsive episode (age 29)\nunvirilized, prepubertal testes, hypogonadal testosterone, undetectable gonadotropins, hypoplastic olfactory sulci, apparent absent OB, normal kidney phenotypes as seen through imaging.","phenotypes":["obo:HP_0000044","obo:HP_0000819","obo:HP_0000458","obo:HP_0025502","obo:HP_0030260","obo:HP_0000771","obo:HP_0003003","obo:HP_0008187"],"sex":"Male","variant":{"id":"cggv:f3f4c58c-fc9e-4b94-93ad-6f992ef312cc_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4a6aea08-07f0-4a89-a900-8c287e86355c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:BiallelicHomozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/17959774","type":"dc:BibliographicResource","dc:abstract":"Gonadotropin-releasing hormone (GnRH) deficiency in the human presents either as normosmic idiopathic hypogonadotropic hypogonadism (nIHH) or with anosmia [Kallmann syndrome (KS)]. To date, several loci have been identified to cause these disorders, but only 30% of cases exhibit mutations in known genes. Recently, murine studies have demonstrated a critical role of the prokineticin pathway in olfactory bulb morphogenesis and GnRH secretion. Therefore, we hypothesize that mutations in prokineticin 2 (PROK2) underlie some cases of KS in humans and that animals deficient in Prok2 would be hypogonadotropic. One hundred IHH probands (50 nIHH and 50 KS) with no known mutations were examined for mutations in the PROK2 gene. Mutant PROK2s were examined in functional studies, and the reproductive phenotype of the Prok2(-/-) mice was also investigated. Two brothers with KS and their sister with nIHH harbored a homozygous deletion in the PROK2 gene (p.[I55fsX1]+[I55fsX1]). Another asymptomatic brother was heterozygous for the deletion, whereas both parents (deceased) had normal reproductive histories. The identified deletion results in a truncated PROK2 protein of 27 amino acids (rather than 81 in its mature form) that lacks bioactivity. In addition, Prok2(-/-) mice with olfactory bulb defects exhibited disrupted GnRH neuron migration, resulting in a dramatic decrease in GnRH neuron population in the hypothalamus as well as hypogonadotropic hypogonadism. Homozygous loss-of-function PROK2 mutations cause both KS and nIHH.","dc:creator":"Pitteloud N","dc:date":"2007","dc:title":"Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism."}},"zygosity":{"id":"cg:BiallelicHomozygous"},"rdfs:label":"II-2"},{"id":"cggv:f3f4c58c-fc9e-4b94-93ad-6f992ef312cc","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:f3f4c58c-fc9e-4b94-93ad-6f992ef312cc_variant_evidence_item"},{"id":"cggv:f3f4c58c-fc9e-4b94-93ad-6f992ef312cc_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"The 27-aa peptide was synthesized and tested to analyze its activity by using a CHO cell line that stably expresses the receptor PROKR2. Full-length human PROK2 potently activated PROKR2 at a low concentration (EC50 = 19 nM). However, the truncated PROK2 could not activate PROKR2 even at very high concentrations (>200 μM). Thus, the truncated form of PROK2 lacks functionality in vitro."}],"strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f87daed0-15d8-4656-8f87-b3c88cbc0e90_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f87daed0-15d8-4656-8f87-b3c88cbc0e90","type":"Proband","allele":{"id":"cggv:5b2d3922-2592-42d4-a2a9-67bdb07cdd17","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.94G>C (p.Gly32Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252840"}},"firstTestingMethod":"PCR","sex":"Male","variant":{"id":"cggv:c30bd198-dab2-4659-a145-a580c8358dcb_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:5b2d3922-2592-42d4-a2a9-67bdb07cdd17"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17054399"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"II-3"},{"id":"cggv:c30bd198-dab2-4659-a145-a580c8358dcb","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:c30bd198-dab2-4659-a145-a580c8358dcb_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:8d38bc7b-7e0b-4913-9b17-5cca29f922ec_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:8d38bc7b-7e0b-4913-9b17-5cca29f922ec","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":17,"allele":{"id":"cggv:4a6aea08-07f0-4a89-a900-8c287e86355c"},"firstTestingMethod":"PCR","phenotypeFreeText":"Prepubertal testosterone and gonadotropin levels","phenotypes":"obo:HP_0030260","sex":"Male","variant":{"id":"cggv:10347496-7313-4f4d-9ea1-dc7690048052_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4a6aea08-07f0-4a89-a900-8c287e86355c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/18682503","type":"dc:BibliographicResource","dc:abstract":"Physiological activation of the prokineticin pathway has a critical role in olfactory bulb morphogenesis and GnRH secretion in mice.","dc:creator":"Abreu AP","dc:date":"2008","dc:title":"Loss-of-function mutations in the genes encoding prokineticin-2 or prokineticin receptor-2 cause autosomal recessive Kallmann syndrome."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Case 3"},{"id":"cggv:10347496-7313-4f4d-9ea1-dc7690048052","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:10347496-7313-4f4d-9ea1-dc7690048052_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:1b1c597b-a763-47aa-9bc0-260472f15bc0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:1b1c597b-a763-47aa-9bc0-260472f15bc0","type":"Proband","allele":{"id":"cggv:4ac27fb2-fc94-4fd5-8a99-1924a83280cd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.161G>A (p.Ser54Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA76545988"}},"sex":"UnknownEthnicity","variant":{"id":"cggv:a61886d6-1f20-4f24-8af8-9edd6e84c9a2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4ac27fb2-fc94-4fd5-8a99-1924a83280cd"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/18985070","type":"dc:BibliographicResource","dc:abstract":"The Kallmann syndrome (KS) combines hypogonadotropic hypogonadism (HH) with anosmia. This is a clinically and genetically heterogeneous disease. KAL1, encoding the extracellular glycoprotein anosmin-1, is responsible for the X chromosome-linked recessive form of the disease. Mutations in FGFR1 or FGF8, encoding fibroblast growth factor receptor-1 and fibroblast growth factor-8, respectively, underlie an autosomal dominant form with incomplete penetrance. Finally, mutations in PROKR2 and PROK2, encoding prokineticin receptor-2 and prokineticin-2, have been found in heterozygous, homozygous, and compound heterozygous states. These two genes are likely to be involved both in monogenic recessive and digenic/oligogenic KS transmission modes. Notably, mutations in any of the above-mentioned KS genes have been found in less than 30% of the KS patients, which indicates that other genes involved in the disease remain to be discovered.","dc:creator":"Dodé C","dc:date":"2009","dc:title":"Kallmann syndrome."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"KS Patient with Variant in Exon 2"},{"id":"cggv:a61886d6-1f20-4f24-8af8-9edd6e84c9a2","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:a61886d6-1f20-4f24-8af8-9edd6e84c9a2_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:0d0bc0ce-365b-468f-a029-26eb4bc577a3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:0d0bc0ce-365b-468f-a029-26eb4bc577a3","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":22,"allele":{"id":"cggv:5ea200f8-abf8-4a5a-8800-1c99e7ed5484","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.167G>C (p.Arg56Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353501067"}},"firstTestingMethod":"Next generation sequencing panels","sex":"Male","variant":{"id":"cggv:f5a4def9-9117-46d6-a2d2-a991b475847f_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:5ea200f8-abf8-4a5a-8800-1c99e7ed5484"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30098700","type":"dc:BibliographicResource","dc:abstract":"To investigate the mutation profiles and clinical characteristics of Chinese males with isolated hypogonadotropic hypogonadism (IHH) and discover new pathogenic genes that cause IHH.","dc:creator":"Zhou C","dc:date":"2018","dc:title":"Mutation profiles and clinical characteristics of Chinese males with isolated hypogonadotropic hypogonadism."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"No. 076"},{"id":"cggv:f5a4def9-9117-46d6-a2d2-a991b475847f","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:f5a4def9-9117-46d6-a2d2-a991b475847f_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:513fd93e-2b44-4ba1-a64a-dcba5fd63766_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:513fd93e-2b44-4ba1-a64a-dcba5fd63766","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":22,"allele":{"id":"cggv:f0319aa0-9529-47c3-86a6-815581d2cfff","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.137G>T (p.Cys46Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353501129"}},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0000458","obo:HP_0040327"],"sex":"Male","variant":{"id":"cggv:94b6c901-6631-41e5-b3e9-e6dfa707d5ea_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:f0319aa0-9529-47c3-86a6-815581d2cfff"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23082007","type":"dc:BibliographicResource","dc:abstract":"Isolated congenital anosmia (ICA) is a rare phenotype defined as absent recall of any olfactory sensations since birth and the absence of any disease known to cause anosmia. Although most cases of ICA are sporadic, reports of familial cases suggest a genetic cause. ICA due to olfactory bulb agenesis and associated to hypogonadotropic hypogonadism defines Kallmann syndrome (KS), in which several gene defects have been described. In KS families, the phenotype may be restricted to ICA. We therefore hypothesized that mutations in KS genes cause ICA in patients, even in the absence of family history of reproduction disorders.","dc:creator":"Moya-Plana A","dc:date":"2013","dc:title":"PROKR2 and PROK2 mutations cause isolated congenital anosmia without gonadotropic deficiency."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"No. 20"},{"id":"cggv:94b6c901-6631-41e5-b3e9-e6dfa707d5ea","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:94b6c901-6631-41e5-b3e9-e6dfa707d5ea_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:3ee4a892-627c-4580-bcaf-10e50fa966f8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:3ee4a892-627c-4580-bcaf-10e50fa966f8","type":"Proband","allele":{"id":"cggv:4514d072-771d-406b-afff-98b8857b2e2b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.150C>G (p.Ile50Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353501103"}},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0008187","obo:HP_0000028","obo:HP_0000458","obo:HP_0001335"],"sex":"Male","variant":{"id":"cggv:ec0a2365-c20d-4ba7-a4da-94a1b5735fea_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4514d072-771d-406b-afff-98b8857b2e2b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/18559922"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Subject no. 2"},{"id":"cggv:ec0a2365-c20d-4ba7-a4da-94a1b5735fea","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:ec0a2365-c20d-4ba7-a4da-94a1b5735fea_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:00df937a-89d4-4779-9945-68380a6b836a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:00df937a-89d4-4779-9945-68380a6b836a","type":"Proband","allele":{"id":"cggv:052b116d-22e3-4199-9b7f-e52a37ebbd25"},"firstTestingMethod":"PCR","sex":"UnknownEthnicity","variant":{"id":"cggv:47e4855a-791e-4221-9d00-d333429e781e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:052b116d-22e3-4199-9b7f-e52a37ebbd25"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17054399"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Sporadic Case 2"},{"id":"cggv:47e4855a-791e-4221-9d00-d333429e781e","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:47e4855a-791e-4221-9d00-d333429e781e_variant_evidence_item"},{"id":"cggv:47e4855a-791e-4221-9d00-d333429e781e_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Signaling properties in an aequorin-based luminescence assay to evaluate intracellular calcium mobilization. The full-length human PROK2 activated PROKR2 at a low concentration (EC50 ∼50 nm). The R73C variant resulted in a 7-fold decreased activity at the EC50 of wild type PMID:18559922"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:c5638449-6db1-434a-b30c-d15e9d8ee35e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:c5638449-6db1-434a-b30c-d15e9d8ee35e","type":"Proband","allele":{"id":"cggv:80f125f6-12dc-4d4b-a30d-3bbe9b19275f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.310C>T (p.His104Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2491961"}},"sex":"UnknownEthnicity","variant":{"id":"cggv:ec2c3604-bd95-46af-b6d1-72d926f999ed_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:80f125f6-12dc-4d4b-a30d-3bbe9b19275f"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/18985070"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"KS Patient with Variant in Exon 4"},{"id":"cggv:ec2c3604-bd95-46af-b6d1-72d926f999ed","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:ec2c3604-bd95-46af-b6d1-72d926f999ed_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:8c6d283c-8fac-4b2d-bba0-6a28ec329181_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:8c6d283c-8fac-4b2d-bba0-6a28ec329181","type":"Proband","allele":{"id":"cggv:beb6683c-8752-488f-833a-7ca4749fc32e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.302G>A (p.Arg101Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2491962"}},"sex":"UnknownEthnicity","variant":{"id":"cggv:043a4139-c12b-49fe-b8fc-ed76148d015f_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:beb6683c-8752-488f-833a-7ca4749fc32e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23596439","type":"dc:BibliographicResource","dc:abstract":"Kallmann syndrome (KS) is a developmental disease that associates hypogonadism and a deficiency of the sense of smell. The reproductive phenotype of KS results from the primary interruption of the olfactory, vomeronasal, and terminal nerve fibers in the frontonasal region, which in turn disrupts the embryonic migration of neuroendocrine gonadotropin-releasing hormone (GnRH) synthesizing cells from the nose to the brain. This is a highly heterogeneous genetic disease, and mutations in any of the nine genes identified so far have been found in approximately 30% of the KS patients. PROKR2 and PROK2, which encode the G protein-coupled prokineticin receptor-2 and its ligand prokineticin-2, respectively, are two of these genes. Homozygous knockout mice for the orthologous genes exhibit a phenotype reminiscent of the KS features, but biallelic mutations in PROKR2 or PROK2 (autosomal recessive mode of disease transmission) have been found only in a minority of the patients, whereas most patients carrying mutations in these genes are heterozygotes. The mutations, mainly missense mutations, have deleterious effects on PROKR2 signaling in transfected cells, ranging from defective cell surface-targeting of the receptor to defective coupling to G proteins or impaired receptor-ligand interaction, but the same mutations have also been found in apparently unaffected individuals, which suggests a digenic/oligogenic mode of inheritance of the disease in heterozygous patients. This non-Mendelian mode of inheritance has so far been confirmed only in a few patients. However, it may account for the unusually high proportion of KS sporadic cases compared to familial cases.","dc:creator":"Dodé C","dc:date":"2013","dc:title":"PROK2/PROKR2 Signaling and Kallmann Syndrome."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Previously Unpublished"},{"id":"cggv:043a4139-c12b-49fe-b8fc-ed76148d015f","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:043a4139-c12b-49fe-b8fc-ed76148d015f_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:879e3732-a064-4000-916a-53c6909a8f18_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:879e3732-a064-4000-916a-53c6909a8f18","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":23,"allele":{"id":"cggv:d9324da4-03a8-4cd7-a49e-0daca05a247b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.297dup (p.Gly100fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2491964"}},"firstTestingMethod":"PCR","phenotypeFreeText":"Decreased serum testosterone concentration, prepubertal basal and GnRH-stimulated gonadotropins","phenotypes":["obo:HP_0000771","obo:HP_0000054","obo:HP_0000458"],"sex":"Male","variant":{"id":"cggv:a753e8b6-1ff1-47a7-b31a-565fe11ec39b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d9324da4-03a8-4cd7-a49e-0daca05a247b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:BiallelicHomozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/18682503"},"zygosity":{"id":"cg:BiallelicHomozygous"},"rdfs:label":"Case 1"},{"id":"cggv:a753e8b6-1ff1-47a7-b31a-565fe11ec39b","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:a753e8b6-1ff1-47a7-b31a-565fe11ec39b_variant_evidence_item"}],"strengthScore":1,"dc:description":"Reduced scored from 1 point per variant due to homozygosity."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:1272276f-3fb4-4ebb-876f-11826dbbb282_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:1272276f-3fb4-4ebb-876f-11826dbbb282","type":"Proband","allele":{"id":"cggv:2fd7be36-aaac-4001-a492-f6908ac5c090","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001126128.2(PROK2):c.301C>T (p.Arg101Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2491963"}},"firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"cggv:64d51a9e-f50b-4b1d-a2c6-55e1c0496a75_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2fd7be36-aaac-4001-a492-f6908ac5c090"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24031091"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Patient with KS (2nd missense variant)"},{"id":"cggv:64d51a9e-f50b-4b1d-a2c6-55e1c0496a75","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:64d51a9e-f50b-4b1d-a2c6-55e1c0496a75_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:2305ec95-325d-4ebe-9401-121705e49660_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:2305ec95-325d-4ebe-9401-121705e49660_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:b9299928-bb75-4b28-9165-c0eec606b4c5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:e9a3083d-7ec2-463b-a03c-fdd38c1ded88","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"PROK2 expression appeared restricted to testis and peripheral blood leukocytes. Northern blot analysis of human and mouse tissues verified these findings. These findings indicate that the testis is the major site of PROK2 expression in both human and rodents.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/12604792","type":"dc:BibliographicResource","dc:abstract":"We recently identified an angiogenic mitogen, endocrine-gland-derived vascular endothelial growth factor (EG-VEGF), with selective activity for endothelial cells of endocrine tissues. Here we describe the characterization of a highly related molecule, Bv8, also known as prokineticin-2. Human Bv8 shares 60% identity and 75% similarity with EG-VEGF. The human and mouse Bv8 genes share a common structure. Like EG-VEGF, Bv8 is able to induce proliferation, survival and migration of adrenal cortical capillary endothelial cells. Bv8 gene expression is induced by hypoxic stress. Bv8 expression occurs predominantly in the testis and is largely restricted to primary spermatocytes. Adenoviral delivery of Bv8 or EG-VEGF to the mouse testis resulted in a potent angiogenic response. We have localized the expression of the Bv8EG-VEGF receptors within the testis to vascular endothelial cells. The testis exhibits relatively high turnover of endothelial cells. Therefore, Bv8 and EG-VEGF, along with other factors such as VEGF-A, may maintain the integrity and also regulate proliferation of the blood vessels in the testis.","dc:creator":"LeCouter J","dc:date":"2003","dc:title":"The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells."},"rdfs:label":"Dot-blot analysis on RNA arrays"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:e42757e6-09cb-4d6d-8705-e0fdd63d0035","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:471565b4-7dc2-4f88-a10b-0675b6c3fbd5","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"PROK2 was shown in the GL and PL of adult OB in a darkfield image and a cresyl violet staining.\n","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15976302","type":"dc:BibliographicResource","dc:abstract":"Neurogenesis persists in the olfactory bulb (OB) of the adult mammalian brain. New interneurons are continually added to the OB from the subventricular zone (SVZ) via the rostral migratory stream (RMS). Here we show that secreted prokineticin 2 (PK2) functions as a chemoattractant for SVZ-derived neuronal progenitors. Within the OB, PK2 may also act as a detachment signal for chain-migrating progenitors arriving from the RMS. PK2 deficiency in mice leads to a marked reduction in OB size, loss of normal OB architecture, and the accumulation of neuronal progenitors in the RMS. These findings define an essential role for G protein-coupled PK2 signaling in postnatal and adult OB neurogenesis.","dc:creator":"Ng KL","dc:date":"2005","dc:title":"Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling."},"rdfs:label":"Staining of PROK2 in the OB"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:0c299e3f-7998-4ea9-9333-841769ff2c44","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:7b96ad88-4782-4875-952e-618df275cc2f","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"PROKR2 is the receptor for PROK2, also implicated in hypogonadotropic hypogonadism.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/12427552","type":"dc:BibliographicResource","dc:abstract":"Recent studies have identified two novel biofunctional proteins, termed prokineticin 1/EG-VEGF and prokineticin 2, which were mammalian homologues of mamba MIT1 and frog Bv8. Prokineticins have been demonstrated to exert their physiological functions through G-protein coupled receptors (GPCRs). In this study, we report the molecular identification of two endogenous prokineticin receptors, designated PK-R1 and PK-R2, through a search of the human genomic DNA database. PK-R1, locating in chromosome 2, and PK-R2, locating in chromosome 20p13, shared 87% homology, which was an extremely high value among known GPCRs. In functional assays, mammalian cells expressing PK-Rs responded to prokineticins in a concentration-dependent manner. Tissue distribution analysis revealed that expression of PK-R1 was observed in the testis, medulla oblongata, skeletal muscle and skin, while that of PK-R2 showed preferential expression in the central nervous system. The tissue distribution of PK-Rs reported in this paper suggests that the prokineticins play multifunctional roles in vivo.","dc:creator":"Soga T","dc:date":"2002","dc:title":"Molecular cloning and characterization of prokineticin receptors."},"rdfs:label":"Luciferase reporter gene assay"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"cggv:a75b20bd-506e-489d-8a5c-41652b47d99c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:2133c0db-2401-4308-a0dc-dcd35a2b0329","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"LOF in PROK2 would lead to failure to modulate GnRH function, causing hypogonadotropic hypogonadism.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19784373","type":"dc:BibliographicResource","dc:abstract":"The suprachiasmatic nucleus (SCN) in the hypothalamus is the predominant circadian clock in mammals. To function as a pacemaker, the intrinsic timing signal from the SCN must be transmitted to different brain regions. Prokineticin 2 (PK2) is one of the candidate output molecules from the SCN. In this study, we investigated the efferent projections of PK2-expressing neurons in the SCN through a transgenic reporter approach. Using a bacterial artificial chromosome (BAC) transgenic mouse line, in which the enhanced green fluorescence protein (EGFP) reporter gene expression was driven by the PK2 promoter, we were able to obtain an efferent projections map from the EGFP-expressing neurons in the SCN. Our data revealed that EGFP-expressing neurons in the SCN, hence representing some of the PK2-expressing neurons, projected to many known SCN target areas, including the ventral lateral septum, medial preoptic area, subparaventricular zone, paraventricular nucleus, dorsomedial hypothalamic nucleus, lateral hypothalamic area and paraventricular thalamic nucleus. The efferent projections of PK2-expressing neurons supported the role of PK2 as an output molecule of the SCN.","dc:creator":"Zhang C","dc:date":"2009","dc:title":"Efferent projections of prokineticin 2 expressing neurons in the mouse suprachiasmatic nucleus."},"rdfs:label":"EGFP-immunostained fibers in suprachiasmatic nucleus"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"cggv:2305ec95-325d-4ebe-9401-121705e49660_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:855169f6-fef4-4cd1-9789-6c9dc3d4c06b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:1aaff22e-d876-412b-bb75-964783302056","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"OB of knockout mice were less than half the size of WT controls with ~50% displaying asymmetric bulb formation as well. Additionally, the granular cell layer was abnormally thin and the number of granular cells were reduced. The periglomerular layer was indiscernible/malformed in knockout mice. The smaller OB of knockout mice had significant enlargement of both the olfactory ventricle (OV) and the rostral migratory stream (RMS) at the entrance of the OB.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15976302","rdfs:label":"Nissl staining of OB in PROK2 KO Mice"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"This study used the same mouse model as the Pitteloud et al. 2007, PMID: 17959774 publication. This piece of evidence is scored at 1 point for accounting for 1/2 of the same mouse model with characteristic phenotypes of the disease."},{"id":"cggv:c6e51049-24cf-49ca-b424-dcf5ed0e45ae","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:4448df43-e9ea-4251-a72c-7705522deeb5","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Obesity, severe sleep disorder, and type 2 diabetes were seen in patients with hypogonadotropic hypogonadism which is likely attributed to the circadian role of PROK2.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/17093083","type":"dc:BibliographicResource","dc:abstract":"Circadian clocks drive daily rhythms in virtually all organisms. In mammals, the suprachiasmatic nucleus (SCN) is recognized as the master clock that synchronizes central and peripheral oscillators to evoke circadian rhythms of diverse physiology and behavior. How the timing information is transmitted from the SCN clock to generate overt circadian rhythms is essentially unknown. Prokineticin 2 (PK2), a clock-controlled gene that encodes a secreted protein, has been indicated as a candidate SCN clock output signal that regulates circadian locomotor rhythm. Here we report the generation and analysis of PK2-null mice. The reduction of locomotor rhythms in PK2-null mice was apparent in both hybrid and inbred genetic backgrounds. PK2-null mice also displayed significantly reduced rhythmicity for a variety of other physiological and behavioral parameters, including sleep-wake cycle, body temperature, circulating glucocorticoid and glucose levels, as well as the expression of peripheral clock genes. In addition, PK2-null mice showed accelerated acquisition of food anticipatory activity during a daytime food restriction. We conclude that PK2, acting as a SCN output factor, is important for the maintenance of robust circadian rhythms.","dc:creator":"Li JD","dc:date":"2006","dc:title":"Attenuated circadian rhythms in mice lacking the prokineticin 2 gene."},"rdfs:label":"Attenuated amplitudes of circadian oscillation."}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"This is the same mouse model used by Xiao L et al. 2014, PMID: 24633064. Therefore, this evidence was scored for 1 point as the Xiao L et al. publication is scored for another 1 point, for 2 points total."},{"id":"cggv:db0f595c-83e0-4f7e-9c8d-0495a48f6df4","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:0bca17c5-26a3-4ff4-b312-f8173aa63165","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"This mouse model supports that PROK2 variation interrupts the pre-ovulatory GnRH surge, partially controlled by circadian outputs from the SCN to GnRH neurons.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24633064","type":"dc:BibliographicResource","dc:abstract":"The possible signaling role of prokineticin 2 (PK2) and its receptor, prokineticin receptor 2 (PKR2), on female reproduction was investigated. First, the expression of PKR2 and its co-localization with estrogen receptor (ERα) in the hypothalamus was examined. Sexually dimorphic expression of PKR2 in the preoptic area of the hypothalamus was observed. Compared to the male mice, there was more widespread PKR2 expression in the preoptic area of the hypothalamus in the female mice. The likely co-expression of PKR2 and ERα in the preoptic area of the hypothalamus was observed. The estrous cycles in female PK2-null, and PKR2-null heterozygous mice, as well as in PK2-null and PKR2-null compound heterozygous mice were examined. Loss of one copy of PK2 or PKR2 gene caused elongated and irregular estrous cycle in the female mice. The alterations in the estrous cycle were more pronounced in PK2-null and PKR2-null compound heterozygous mice. Consistent with these observations, administration of a small molecule PK2 receptor antagonist led to temporary blocking of estrous cycle at the proestrous phase in female mice. The administration of PKR2 antagonist was found to blunt the circulating LH levels. Taken together, these studies indicate PK2 signaling is required for the maintenance of normal female estrous cycles. ","dc:creator":"Xiao L","dc:date":"2014","dc:title":"Signaling role of prokineticin 2 on the estrous cycle of female mice."},"rdfs:label":"Loss of one copy of PROK2 disrupts estrous cycles"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"This is the same mouse model used in Li et al. 2006. PMID:17093083. Therefore, this evidence is scored for 1 point as this mouse model detailed by Li et al. is scored for 1 point as well, for a total of 2 points."},{"id":"cggv:21296659-d4ec-46e7-8496-2952c015d94d","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:cbf92ef2-7de1-4afd-888d-7fa3e0dae6e7","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"This phenotype, hypogonadotropic hypogonadism, is seen in human patients with pathogenic variants in PROK2.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17959774","rdfs:label":"Anatomical examination of PROK2 -/- mice"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"This study used the same mouse model as the Ng KL et al. 2005, PMID: 15976302 publication. This piece of evidence is scored at 1 point for accounting for greater detail of the same mouse model with additional characteristic phenotypes of hypogonadotropic hypogonadism 4 with or without anosmia."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":4541,"specifiedBy":"GeneValidityCriteria8","strengthScore":18,"subject":{"id":"cggv:53a6b92d-6574-444d-8ae7-5d41ad677da4","type":"GeneValidityProposition","disease":"obo:MONDO_0012528","gene":"hgnc:18455","modeOfInheritance":"obo:HP_0032113"},"version":"1.1","dc:description":"PROK2 was first reported in relation to autosomal dominant Hypogonadotropic hypogonadism 4 with or without anosmia in 2006 (Dodé et al., PMID: 17054399). Hypogonadotropic hypogonadism is a disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. This can be caused by an isolated defect in gonadotropin-releasing hormone release, action, or both. Other associated nonreproductive phenotypes, such as anosmia, cleft palate, diabetes, sleep disorder, and sensorineural hearing loss, occur with variable frequency. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no differences in molecular mechanisms, inheritance patterns, and phenotypic variability. Therefore, the following disease entities have been lumped into one disease entity, hypogonadotropic hypogonadism 4 with or without anosmia (OMIM:610628), Kallman syndrome (KS), and  normosic congenital (idiopathic) hypogonadotropic hypogonadism (nIHH) in a semidominant inheritance pattern. Eighteen variants (missense, nonsense, frameshift, duplication, and insertion) that have been reported in 23 probands in 14 publications (PMIDs: 17054399, 17959774, 18559922, 18682503, 18985070, 23082007, 23596439, 24002956, 24031091, 25077900, 26141714, 30098700, 32870266, 33140874) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is known to be LOF. This gene-disease association is also supported by experimental evidence (animal models, expression studies, biochemical function, and protein interaction) (PMIDs: 12427552, 12604792, 15976302, 17093083, 17959774, 19784373, 24633064). One mouse model phenocopies hypogonadotropic hypogonadism and the expression study demonstrates PROK2 involvement in olfactory bulb neurogenesis. Another mouse model demonstrates that LOF in PROK2 can cause attenuated estrous cycles along with other circadian rhythms including sleep cycles and blood glucose regulation. PROK2 is expressed in the olfactory bulb and testis, proposed to modulate GnRH release as an SCN output molecule regulating circadian rhythms, and interacts with PROKR2 which is definitively associated with hypogonadotropic hypogonadism. In summary, PROK2 is definitively associated with semidominant Hypogonadotropic hypogonadism 4 with or without anosmia. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This has been approved by the ClinGen Brain Malformations Gene Curation Expert Panel on 03/22/2022 (SOP Version 8).","dc:isVersionOf":{"id":"cggv:2305ec95-325d-4ebe-9401-121705e49660"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}